Insights into endometrial cancer profiles and its pattern of recurrences: a study from a leading health center in eastern Morocco
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20250166Keywords:
Endometrial cancer, Morocco, North Africa, Postmenopausal, Prognosis, Recurrence, Risk factorsAbstract
- Background: Endometrial cancer (EC) is a rising gynecological malignancy, particularly in low- and middle-income countries. This study explored the demographic, clinical, and pathological features of women with EC in eastern Morocco.
Methods: A retrospective review of 60 cases of histologically confirmed EC was conducted at Mohammed VI University Hospital, Oujda, from January 2016 to January 2024. Data included demographics, clinical symptoms, diagnostics, treatments, and risk factors.
Results: The mean age was 56 years, with 80% aged 50-70. Most patients (60%) resided in urban areas, and 90% were nonsedentary housewives. Vaginal bleeding was the main symptom (87%). Early-stage disease (stage I) was predominant (70%), with endometrioid carcinoma accounting for 65% of cases. Tumor grades were 40% grade I, 45% grade II, and 15% grade III, with >50% myometrial invasion in 45%. Risk factors included postmenopausal status (80%), nulliparity (43%), and overweight (46%), while hypertension and diabetes affected 30% and 20%, respectively. Treatment involved total hysterectomy with bilateral salpingo-oophorectomy (45%) or radical hysterectomy (18.3%). Adjuvant therapy was administered to 76.7%, with 11.7% receiving combined chemo-radiotherapy. Based on ESMO-ESGO-ESTRO risk classification, 60% were low-risk, while high-risk cases showed higher recurrence and poorer outcomes.
Conclusions: EC in Morocco is often detected at an early stage, predominantly affecting postmenopausal women. Efforts should focus on early diagnosis and customized treatment strategies for high-risk patients to improve outcomes.
Metrics
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clinicians. 2021;71(3):209-49. DOI: https://doi.org/10.3322/caac.21660
Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global cancer in women: burden and trends. Cancer Epidemiol Biomarke Prevent. 2017;26(4):444-57. DOI: https://doi.org/10.1158/1055-9965.EPI-16-0858
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5). DOI: https://doi.org/10.1002/ijc.29210
Temkin SM, Kohn EC, Penberthy L, Cronin KA, Rubinsak L, Dickie LA, et al. Hysterectomy-corrected rates of endometrial cancer among women younger than age 50 in the United States. Cancer Causes Control. 2018;29(4–5):427-33. DOI: https://doi.org/10.1007/s10552-018-1018-z
Gottwald L, Pluta P, Piekarski J, Spych M, Hendzel K, Topczewska-Tylinska K, et al. Long-term survival of endometrioid endometrial cancer patients. AOMS. 2010;6:937-44. DOI: https://doi.org/10.5114/aoms.2010.19305
Van den Bosch A, Mertens H. Implementation of laparoscopic surgery for endometrial cancer: work in progress. Facts Views Vis Obgyn. 2016;8(1):23-30.
Nicholas Z, Hu N, Ying J, Soisson P, Dodson M, Gaffney DK. Impact of comorbid conditions on survival in endometrial cancer. Am J Clin Oncol. 2014;37(2):131-4. DOI: https://doi.org/10.1097/COC.0b013e318277d5f4
Raglan O, Kalliala I, Markozannes G, Cividini S, Gunter MJ, Nautiyal J, et al. Risk factors for endometrial cancer: an umbrella review of the literature. Int J Cancer. 2019;145(7):1719-30. DOI: https://doi.org/10.1002/ijc.31961
Onstad MA, Schmandt RE, Lu KH. Addressing the role of obesity in endometrial cancer risk, prevention, and treatment. J Clin Oncol. 2016;34(35):4225-30. DOI: https://doi.org/10.1200/JCO.2016.69.4638
King L, Gajarawala S, McCrary MD. Endometrial cancer and obesity: addressing the awkward silence. JAAPA. 2023;36(1):28-31. DOI: https://doi.org/10.1097/01.JAA.0000902884.01725.a3
Jimenez JS, Tejerizo-Garcia A, Munoz-Gonzalez JL, Bartolomé-Sotillos S, Marqueta-Marqués L, López-González G, et al. Overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients. OTT. 2013;1305. DOI: https://doi.org/10.2147/OTT.S51532
Angadi V, Praisy E, Tatineni T, Karpurmath SV, Nandennavar MI. Clinicopathological features and prognostic factors in endometrial carcinoma: a retrospective analysis from a tertiary cancer centre. Int J Res Med Sci. 2022;10(9):1925. DOI: https://doi.org/10.18203/2320-6012.ijrms20222266
Soslow RA, Tornos C, Park KJ, Malpica A, Matias-Guiu X, Oliva E, et al. Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the International Society of Gynecological Pathologists. Int J Gynecol Pathol. 2019;38(Supplement 1):S64-74. DOI: https://doi.org/10.1097/PGP.0000000000000518
Azueta A, Gatius S, Matias-Guiu X. Endometrioid carcinoma of the endometrium: pathologic and molecular features. Semin Diagn Pathol. 2010;27(4):226-40. DOI: https://doi.org/10.1053/j.semdp.2010.09.001
Brooks RA, Fleming GF, Lastra RR, Lee NK, Moroney JW, Son CH, et al. Current recommendations and recent progress in endometrial cancer. CA Cancer J Clin. 2019;69(4):258-79. DOI: https://doi.org/10.3322/caac.21561
Wright JD. Take ’em or leave ’em: management of the ovaries in young women with endometrial cancer. Gynecol Oncol. 2013;131(2):287-8. DOI: https://doi.org/10.1016/j.ygyno.2013.09.026
Matsuo K, Machida H, Shoupe D, Melamed A, Muderspach LI, Roman LD, et al. Ovarian conservation and overall survival in young women with early-stage low-grade endometrial cancer. Obstet Gynecol. 2016;128(4):761-70. DOI: https://doi.org/10.1097/AOG.0000000000001647
Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, et al. Uterine Neoplasms, Version 1.2023, NCCN Clinical Practice Guidelines in Oncology. J Nat Comprehens Cancer Network. 2023;21(2):181-209. DOI: https://doi.org/10.6004/jnccn.2023.0006
Creasman WT, Morrow CP, Bundy BN, Homesley HD, Graham JE, Heller PB. Surgical pathologic spread patterns of endometrial cancer: a gynecologic oncology group study. Cancer. 1987;60(S8):2035-41. DOI: https://doi.org/10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8
Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study. Lancet. 2009;373(9658):125-36. DOI: https://doi.org/10.1016/S0140-6736(08)61766-3
Panici PB, Basile S, Maneschi F, Lissoni AA, Signorelli M, Scambia G, et al. Systematic pelvic lymphadenectomy vs no lymphadenectomy in early-stage endometrial carcinoma: randomized clinical trial. J Nat Cancer Inst. 2008;100(23):1707-16. DOI: https://doi.org/10.1093/jnci/djn397
Mariani A, Keeney GL, Aletti G, Webb MJ, Haddock MG, Podratz KC. Endometrial carcinoma: paraaortic dissemination. Gynecol Oncol. 2004;92(3):833-8. DOI: https://doi.org/10.1016/j.ygyno.2003.11.032
Daraï E, Dubernard G, Bats AS, Heitz D, Mathevet P, Marret H, et al. Sentinel node biopsy for the management of early stage endometrial cancer: long-term results of the SENTI-ENDO study. Gynecol Oncol. 2015;136(1):54-9. DOI: https://doi.org/10.1016/j.ygyno.2014.09.011
Rossi EC, Kowalski LD, Scalici J, Cantrell L, Schuler K, Hanna RK, et al. A comparison of sentinel lymph node biopsy to lymphadenectomy for endometrial cancer staging (FIRES trial): a multicentre, prospective, cohort study. Lancet Oncol. 2017;18(3):384-92. DOI: https://doi.org/10.1016/S1470-2045(17)30068-2
DiSaia PJ. Predicting parametrial involvement in endometrial cancer: is this the end for radical hysterectomies in stage II endometrial cancers? Obstet Gynecol. 2010;116(5):1016-7. DOI: https://doi.org/10.1097/AOG.0b013e3181f98202
Takano M, Ochi H, Takei Y, Miyamoto M, Hasumi Y, Kaneta Y, et al. Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)? Br J Cancer. 2013;109(7):1760-5. DOI: https://doi.org/10.1038/bjc.2013.521
Vargo JA, Boisen MM, Comerci JT, Kim H, Houser CJ, Sukumvanich P, et al. Neoadjuvant radiotherapy with or without chemotherapy followed by extrafascial hysterectomy for locally advanced endometrial cancer clinically extending to the cervix or parametria. Gynecol Oncol. 2014;135(2):190-5. DOI: https://doi.org/10.1016/j.ygyno.2014.09.001
Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol. 2010;118(1):14-8. DOI: https://doi.org/10.1016/j.ygyno.2010.04.005
Wilkinson-Ryan I, Frolova AI, Liu J, Stewart Massad L, Thaker PH, Powell MA, et al. Neoadjuvant chemotherapy versus primary cytoreductive surgery for stage IV uterine serous carcinoma. Int J Gynecol Cancer. 2015;25(1):63-8. DOI: https://doi.org/10.1097/IGC.0000000000000321
Vandenput I, Van Calster B, Capoen A, Leunen K, Berteloot P, Neven P, et al. Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment? Br J Cancer. 2009;101(2):244-9. DOI: https://doi.org/10.1038/sj.bjc.6605157
Sorbe BG, Horvath G, Andersson H, Boman K, Lundgren C, Pettersson B. External pelvic and vaginal irradiation versus vaginal irradiation alone as postoperative therapy in medium-risk endometrial carcinoma: a prospective, randomized study- quality-of-life analysis. Int J Gynecol Cancer. 2012;22(7):1281-8. DOI: https://doi.org/10.1097/IGC.0b013e3182643ba0
Nout R, Smit V, Putter H, Jürgenliemk-Schulz I, Jobsen J, Lutgens L, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet. 2010;375(9717):816-23. DOI: https://doi.org/10.1016/S0140-6736(09)62163-2
Randall ME, Filiaci V, McMeekin DS, von Gruenigen V, Huang H, Yashar CM, et al. Phase III trial: adjuvant pelvic radiation therapy versus vaginal brachytherapy plus paclitaxel/carboplatin in high-intermediate and high-risk early stage endometrial cancer. J Clin Oncol. 2019;37(21):1810-8. DOI: https://doi.org/10.1200/JCO.18.01575
De Boer SM, Powell ME, Mileshkin L, Katsaros D, Bessette P, Haie-Meder C, et al. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(3):295-309. DOI: https://doi.org/10.1016/S1470-2045(18)30079-2
Matei D, Filiaci V, Randall ME, Mutch D, Steinhoff MM, DiSilvestro PA, et al. Adjuvant chemotherapy plus radiation for locally advanced endometrial cancer. N Engl J Med. 2019;380(24):2317-26. DOI: https://doi.org/10.1056/NEJMoa1813181
Zheng W. Molecular classification of endometrial cancer and the 2023 FIGO Staging: exploring the challenges and opportunities for pathologists. Cancers. 2023;15(16):4101. DOI: https://doi.org/10.3390/cancers15164101
Vizza E, Cutillo G, Bruno V, Sperduti I, Mancini E, Baiocco E, et al. Pattern of recurrence in patients with endometrial cancer: a retrospective study. Eur J Surg Oncol. 2020;46(9):1697-702. DOI: https://doi.org/10.1016/j.ejso.2020.03.203
Bendifallah S, Ouldamer L, Lavoue V, Canlorbe G, Raimond E, Coutant C, et al. Patterns of recurrence and outcomes in surgically treated women with endometrial cancer according to ESMO-ESGO-ESTRO Consensus Conference risk groups: results from the FRANCOGYN study group. Gynecol Oncol. 2017;144(1):107-12. DOI: https://doi.org/10.1016/j.ygyno.2016.10.025
Downloads
Published
How to Cite
Issue
Section
